Effect of silymarin on liver phoshpatidate phosphohydrolase in hyperlipidemic rats

Bioscience Research

Volumn 9, Issue 2, 2012, Pages 59-67

  Heidarian, E ^a   Rafieian Kopaei, M ^a  

^a SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hyperlipidemia; Liver triglyceride; Phosphatidate phosphohydrolase; Plasma lipids; Silymarin

Indexed keywords

EID: 84877975548     PISSN: 18119506     EISSN: 22183973     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Andersen C, Rayalam S, Della-Fera MA, Baile CA, 2010. Phytochemicals and adipogenesis. Biofactors. 36: 415-422.
2. Anfossi G, Massucco P, Bonomo K, Trovati M, 2004. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr. Metab. Cardiovasc. Dis. 14: 215-424.
3. Basiglio CL, Sánchez Pozzi EJ, Mottino AD, Roma MG, 2009. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem. Biol. Interact. 179: 297-303.
4. Benzie IF, Strain JJ, 1996. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem. 239: 70-76.
5. Bradford MM, 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
6. Carman GM, Han GS, 2006. Roles of phosphatidate phosphatase enzymes in lipid metabolism. Trends Biochem. Sci. 31: 694-699.
7. Dixit N, Baboota S, Kohli K, Ahmad S, Ali J, 2007. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol. 39: 172-179.
8. Elabbadi N, Day CP, Gamouh A, Zyad A, Yeaman SJ, 2005. Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. Biochimie 87: 437-443.
9. Fleming IN, Yeaman SJ, 1995. Purification and characterization of N-ethylmaleimide-insensitive phosphatidic acid phosphohydrolase (PAP2) from rat liver. Biochem. J. 308 (Pt 3): 983-989.
10. Friedewald WT, Levy RI, 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
11. Gazák R, Walterová D, Kren V, 2007. Silybin and silymarin-new and emerging applications in medicine. Curr. Med. Chem. 14: 315-338.
12. Goldstein JL, Brown MS, 1984. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J. Lipid Res. 25: 1450-1461.
13. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR (2007). Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin. Ther. 29: 778-794.
14. Heidarian E, Haghighi B, 2008. Enzymological characteristic of plasma membrane phosphatidate phosphohydrolase (PAP2) from rat liver. Iran. J. Sci. Technol. A 32: 117-122.
15. Heidarian E, Jafari-Dehkordi E, Seidkhani-Nahal A, 2011. Effect of garlic on liver phosphatidate phosphohydrolase and plasma lipid levels in hyperlipidemic rats. Food Chem. Toxicol. 49: 1110-1114.
16. Juan MY, Chou CC, 2009. Enhancement of antioxidant activity, total phenolic and flavonoid content of black soybeans by solid state fermentation with Bacillus subtilis BCRC 14715. Food Microbiol. 27: 586-591.
17. Küskü-Kiraz Z, Mehmetçik G, Dogru-Abbasoglu S, Uysal M, 2010. Artichoke leaf extract reduces oxidative stress and lipoprotein dyshomeostasis in rats fed on high cholesterol diet. Phytother. Res. 24: 565-570.
18. Maron DJ, 2004. Flavonoids for reduction of atherosclerotic risk. Curr. Atheroscler. Rep. 6: 73-78.
19. Metwally M, El-Gellal A, El-Sawaisi S, 2009. Effects of silymarin on lipid metabolism in rats. World Appl. Sci. J. 6: 1634-1637.
20. Norman SR, Preparation of lipid extracts. In: John MI. (Ed.), Methods of Enzymology. Academic Press, London; 1969. Vol. 14.
21. Ohkawa H, Ohishi N, Yagi K, 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358.
22. Ondrejovičová I, Muchová J, Mišl'anová C, Nagyová Z, Duračková Z, 2010. Hypercholesterolemia, oxidative stress and gender dependence in children. Prague Med. Rep. 111: 300-312.
23. Petersen KF, Shulman GI, 2006. Etiology of insulin resistance. Am. J. Med. 119: S10-S16.
24. Post-White J, Ladas EJ, Kelly KM, 2007. Advances in the use of milk thistle (Silybum marianum). Integr. Cancer Ther. 6: 104-109.
25. Reue K, Phan J, 2006. Metabolic consequences of lipodystrophy in mouse models. Curr. Opin. Clin. Nutr. Metab. Care 9: 436-441.
26. Rudel LL, 1997. Genetic factors influence the atherogenic response of lipoproteins to dietary fat and cholesterol in nonhuman primates. J. Am. Coll. Nutr. 16: 306-312.
27. Skottová N, Večeřa R, Urbánek K, Vána P, Walterová D, Cvak L, 2003. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacol. Res. 47: 17-26.
28. Sobolová L, Skottová N, Večeřa R, Urbánek K, 2006. Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol. Res. 53: 104-112.
29. Sorci-Thomas M, Prack MM, Dashti N, Johnson F, Rudel LL, Williams DL, 1989. Differential effects of dietary fat on the tissue-specific expression of the apolipoprotein A-I gene: relationship to plasma concentration of high density lipoproteins. J. Lipid Res. 30: 1397-1403.
30. Theriault A, Wang Q, Van Iderstine SC, Chen B, Franke AA, Adeli K, 2000. Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid. J. Lipid Res. 41: 1969-1979.
31. Turley SD, 2004. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin. Cardiol. 27: III16-21.
32. van Herpen NA, Schrauwen-Hinderling VB, 2008. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 94: 231-241.
33. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC, 2008. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab. Dispos. 36:65-72.
34. Yanagita T, Han SY, Wang YM, Tsuruta Y, Anno T, 2003. Cycloalliin, a cyclic sulfur imino acid, reduces serum triacylglycerol in rats. Nutrition 19: 140-143.
35. Yanardag R, Peksel A, Yesilyaprak B, Doger MM, Arisan-Atac I, 2005. Effects of a combination of niacin and chromium (III)-chloride on the skin and lungs of hyperlipemic rats. Biol. Trace Elem. Res. 103: 249-260.